Multiparametric magnetic resonance imaging (mpMRI) and prostate-specific membrane antigen positron emission tomography (PSMA PET) scans have revolutionized prostate cancer imaging, allowing for the more accurate detection of clinically significant disease and better assessment of local and distant tumor spread [14,15,16,17]. This evidence concerns the gene FOLH1 and neoplasm.